The share price of Laurus Labs surged to a fresh 52-week high of ₹581.70 on Monday, December 2, 2024. The stock opened at ₹564 on the NSE, slightly lower than its previous close of ₹567.15. Notably, the day’s opening price also marked the lowest point of the session.
Currently trading at ₹580.45, the stock has seen a northward movement for three consecutive days.
Last week, Laurus Labs’ registering a gain of over 10%. In the month of November, the stock gained over 15%.
The company is set to participate in the Jefferies India: Healthcare & Pharma Trip in Hyderabad on December 4, 2024. This event presents an excellent platform for Laurus Labs to showcase its achievements and future strategies, particularly its evolution into a respected and diversified Contract Development and Manufacturing Organisation (CDMO).
Laurus Labs reported robust financial results in Q2FY25, with revenue reaching ₹1,224 crore despite pricing pressures in generic APIs. This highlights the company’s resilience and business quality, underpinned by its long-term investment strategies and integrated manufacturing capabilities.
Founded in 2005, Laurus Labs has grown into a global leader in Active Pharmaceutical Ingredients (APIs) across key therapeutic areas, including Anti-retroviral, Oncology, Cardiovascular, and Gastroenterology. The company’s backward integration capabilities and commitment to regulatory compliance have solidified its position in the pharmaceutical value chain.
Laurus Labs continues to develop innovative medicines that improve health outcomes worldwide, cementing its reputation as a research-driven pharmaceutical manufacturing powerhouse.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
